Speakers

Rick Anderson
Company Group Chairman, Johnson & Johnson
Worldwide Franchise Chairman, Cordis Corporation

 

 

Rick Anderson is responsible for global leadership of the cardiovascular medical devices franchise within Johnson & Johnson, which includes Cordis Cardiology, Cordis Endovascular, Cordis Neurovascular, and Conor Medsystems. Prior to this position, he was Worldwide President, Cordis Cardiology. He joined Cordis Cardiology as Vice President, Sales and Marketing. Prior to Cordis, he was Vice President, Immunology Franchise, at Centocor, Inc., which merged with Johnson & Johnson in 1999. He has also served in senior leadership positions with other international health care and medical device companies. He holds a Bachelor of Business Administration in Marketing from Mississippi State University. 

Anthony Atala, MD
Professor and Director
Wake Forest Institute for Regenerative Medicine
Chair of the Department of Urology
Wake Forest University School of Medicine
Founder, Tengion

 

Anthony Atala, MD, heads a team of over 100 physicians and researchers, and his current work focuses on growing new human cells, tissues and organs (including kidney, blood vessels, cartilage, muscle, bladder, and pancreas). He is the editor of seven books, including Tissue Engineering and Methods of Tissue Engineering (Academic Press), and has published more than 200 journal articles or book chapters, more than 250 abstracts, and has applied for or received over 200 national and international patents.  He has received numerous awards and honors, including the US Congress funded Christopher Columbus Foundation Award. In 2006, he was named by Fast Company magazine as one of 50 people who “will change how we work and live over the next 10 years.” A Time Magazine poll ranked him the 56th most influential person of the year in 2007.

Matthew Bishop
Chief Business Writer/American Business Editor
New York Bureau Chief
The Economist

 

Matthew Bishop has written several Economist special survey supplements, including "Kings of Capitalism," which anticipated and analyzed the recent boom in private equity. Before joining The Economist, he was on the faculty of London Business School, where he co-authored three books on subjects ranging from privatization and regulation to corporate mergers. He was on the Sykes Commission on the investment system in the 21st Century, and on the Advisors Group of the United Nations International Year of Microcredit 2005. He has been honored as a Young Global Leader by the World Economic Forum and is an Oxford University graduate.

Clayton M. Christensen, MBA '79, DBA '92
Robert and Jane Cizik Professor of Business Administration
Harvard Business School

Clayton M. Christensen’s research and teaching center on managing innovation and creating new growth markets. He has authored or co-authored award-winning, best-selling books, including The Innovator’s Dilemma. Prior to HBS, Christensen was chairman and president of CPS Corporation, a materials science firm he co-founded. He has served as a White House Fellow, and was a member of the staff of the Boston Consulting Group. He holds a BA with highest honors in economics from Brigham Young University, and an MPhil in applied econometrics and the economics of less-developed countries from Oxford University, where he was a Rhodes Scholar. He received a Harvard MBA with High Distinction, graduating as a George F. Baker Scholar, and also received his DBA from HBS.

Paul Corrigan, PhD
Director of Strategy and Commissioning
National Health Service (NHS) London, UK

Paul Corrigan heads strategy and commissioning at NHS London, part of the publicly funded health care system in the United Kingdom. He is also adjunct professor of public health at the Chinese University of Hong Kong. Previously, he was health advisor to Prime Minister Tony Blair, and before that, special advisor to the Secretary of States for Health. He has worked for the Office for Public Management, and authored Shakespeare on Management. He has been a local government consultant on issues of modernization. He gained his first degree in social policy from the London School of Economics, and his PhD at the University of Durham.

John F. Crowley, MBA ‘97
President and CEO
Amicus Therapeutics

2007 Recipient, Beatrice D. Ellerin Award


John Crowley has founded two biotechnologies companies: Novazyme Pharmaceuticals, (sold to Genzyme Therapeutics), and Orexigen Therapeutics. He was previously in senior management at Bristol-Myers Squibb. His involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease. His story has been profiled The Cure by Pulitzer prize winner Geeta Anand, and in the media (The Wall Street Journal, The Today Show, and more). He earned a BS from Georgetown University, a JD from the University of Notre Dame Law School, and an MBA from HBS.  He is a commissioned officer in the US Navy Reserve (active).

Robert A. DeNoble, MBA '72
President and CEO
The Marino Foundation for Integrative Medicine, Inc.
President, HBS Health Industry Alumni Association

Robert DeNoble has over 25 years of experience as a senior executive of healthcare organizations and as a consultant to health care providers and early stage biotech companies. In addition to his role as CEO of the Marino Foundation, he serves as a principal with RDA Healthcare Consulting, Inc., a company he co-founded to provide strategic, operational and financial management services to healthcare organizations. Prior to his current positions, he held senior positions with KPMG, LLP, Rhode Island Hospital, and McLean Hospital. He serves on the Board of the Austen Riggs Center, a national renowned psychiatric hospital located in western Massachusetts.

David Ewing Duncan
Journalist and Author
Chief Correspondent, "Biotech Nation" on NPR
Director, Center for Life Science Policy, UC Berkeley

 

David Ewing Duncan is an award-winning journalist and a best-selling author with six books published in 19 languages. His most recent book, Masterminds: Genius, DNA, and the Quest to Rewrite Life, was named a Best Book of the Year by the San Francisco Chronicle. He was a special correspondent and producer for ABC’s Nightline; is a correspondent for NOVA and an Executive Producer for Smithsonian Networks; and a commentator for NPR’s “Morning Edition.” He is the founder and director of the BioAgenda Institute for Life Sciences Policy, a San Francisco-based nonprofit think-tank. He has won the prestigious AAAS Magazine Journalism Award.

Beatrice Ellerin, MBA '95
Managing Director, Interbrand Wood
Founder, Past President, and Chairman, HBS Health Industry Alumni Association

 

Beatrice Ellerin, known as Bunny, heads up the rxmark division at Interbrand Wood, a leading healthcare branding agency. She focuses on brand research and works closely with senior management to drive business growth. Previously, she was Executive Director of PPD Online Marketing & Education, Inc., where she directed corporate strategy, business development and global marketing. She has been a Vice President at Vivra Specialty Partners, where she managed risk contracts and clinical data reporting for 14 single specialty networks. She received a BA in Political Science from Columbia University. As Chairman, Founder and past President of HBS Health, she led the group's growth into a major HBS alumni association.

Diana Farrell, MBA '91
Director
McKinsey Global Institute

 

 

Diana Farrell is the Director of the McKinsey Global Institute (MGI), the economics research arm of McKinsey & Company. MGI’s independent investigations combine McKinsey’s microeconomic understanding of companies and industries with the rigor of leading macroeconomic thinking to derive perspectives and publish reports on important global economic issues.  She was previously a McKinsey partner in the Washington, DC office. She has served clients around the world in a variety of capacities. She has a BA from Wesleyan University in Economics and in the College of Social Studies.  She also holds an MBA from Harvard Business School.   

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)

 

Anthony S. Fauci, MD, has been Director of the NIAID since 1984, overseeing extensive research to prevent, diagnose, and treat infectious diseases such as HIV/AIDS, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. He is a key advisor to the White House and Department of Health and Human Services on global AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats such as pandemic influenza. He began at the NIAID as a clinical associate in the Laboratory of Clinical Investigation (LCI), later became Head of its Clinical Physiology Section, and was then appointed Chief of the Laboratory of Immunoregulation, a position he still holds. He is author, coauthor, or editor of more than 1,000 scientific publications, including several textbooks. He received his MD from Cornell University Medical College.

Barnaby Feder
Reporter
The New York Times

 

 

Barnaby Feder's technology beat centers on medical devices, with occasional coverage of nanotechnology, radio-frequency identification and environmental technologies. He joined The New York Times in 1980 as a technology reporter,  and has had postings as a general business reporter to London and Chicago. In addition to his technology assignments, he has taken on various editorial jobs for the Times' business section. He previously worked at World Business Weekly, Energy User News, and was a freelance reporter in Scandinavia. He began his career as a reporter and photographer at the North Adams (Mass.) Transcript. He received a BA from Williams College and a JD from the University of California at Berkeley Law School.

David Green, MBA ‘91
President
Harvard Bioscience
Co-Chair, 8th Annual HBS Health Industry Conference

David Green is Co-Founder, President and a Director of Harvard Bioscience, named one of America’s Top 25 Fastest Growing Technology Companies in 2005 by Forbes Magazine. Harvard Bioscience’s products are used to advance life science research at virtually all pharmaceutical and biotechnology companies and research universities worldwide. Previously, he was a strategy consultant with Monitor Company, where his work advising the South African government received international media coverage. Before that, he was a brand manager at Lever Brothers (Unilever). He graduated with honors in physics from Oxford University, and received his Harvard MBA with distinction. He is a co-inventor on the patent Photoacoustic Spectroscopy Sample Array Vessel.

Marc H. Hedrick, MD
President
Cytori Therapeutics

 

Marc Hedrick was appointed President in May 2004. He joined Cytori Therapeutics as Chief Scientific Officer, Medical Director and Director in October 2002. Previously, he co-founded, and served as President and Chief Executive Officer of StemSource, Inc., a company specializing in stem cell research and development. He is a plastic surgeon, and is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). From 1998 until 2005, he directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. He obtained his MD from the University of Texas Southwestern Medical School, Dallas and an MBA from UCLA Anderson School of Management.

Scott Hensley
News Editor
The Wall Street Journal

 

 

Scott Hensley edits and contributes to The Wall Street Journal's Health Blog (http://blogs.wsj.com/health). He joined the Journal in 2000 and covered health care and the pharmaceutical industry for seven years. He also wrote "Follow the Money," an online column about the health-care industry. His story about Pfizer Inc.'s failed attempt to develop an anti-aging pill was part of a series that won a New York Press Club award. Previously, he wrote for Modern Healthcare and American Banker. He earned a bachelor's degree in natural sciences from Johns Hopkins University and a master's degree from Columbia University's Graduate School of Journalism.

 

Michael C. Howe
Chief Executive Officer
MinuteClinic

 

Michael Howe joined MinuteClinic in 2005 and has grown the concept from just 19 clinics in two states to more than 180 clinics in 20 states. He was previously president and CEO of Arby’s Inc, where he steered the company through a challenging turnaround. His leadership resulted in a 50 percent increase in EBITDA, 17 consecutive quarters of same-store sales growth and a stock price that nearly doubled. He was named Businessman of the Year for the state of Florida in 2003 and 2004, and was most recently recognized by Fast Company magazine as one of the top 50 people that will change how Americans work and live over the next 10 years.

Robert S. Huckman, PhD
Associate Professor of Business Administration
Harvard Business School

 

 

Robert Huckman is the MBA Class of 1958 Associate Professor of Business Administration at Harvard Business School. He teaches the second-year course in Operations Strategy and has taught executive education programs and the first-year course in Technology and Operations Management. He is a Faculty Research Fellow in the health care program of the National Bureau of Economic Research and is a member of the HBS Healthcare Initiative. His research focuses on the linkages between organizational characteristics, technological choice, and operating performance, with an emphasis on the health care industry. He received a PhD in Business Economics from Harvard University and an AB in Public Policy, summa cum laude, from Princeton University, where he was elected to Phi Beta Kappa.

James Hummer, MBA ‘80
Founder, President and CEO
Whole Health Management

 

 

Jim Hummer heads Whole Health Management, an innovative provider of direct contract, on-site employee health services to leading self-insured companies. It provides integrated health services including occupational, preventive, urgent and primary health care services, health risk and disease management, physical therapy, fitness programs and behavioral health services. Clients include Sprint, Qualcomm, Florida Power & Light, Continental Airlines and Harrah’s Entertainment. Before Whole Health, he co-founded and was president of the Ivy Medical Group, an ambulatory health care company. Previously, he was Director of Planning and Human Resources at Martin Marietta Corporation’s Chemical Group. Earlier, he was with Deloitte, Haskins & Sells. He holds a BA in accounting from the University of Notre Dame and his MBA from Harvard.

Alice Jacobs, MD
Founder, Chairman and Chief Executive Officer
Intelligent Medical Devices

 

 

Alice Jacobs founded IntelligentMD with the goal to improve efficiency in healthcare delivery, increase the confidence of clinicians and reduce the cost of care worldwide. She performed her first scientific experiments at Stanford University at 16 years old and was published at 19. In 2004, Scientific American named her one of the top 50 innovators in science and technology. The World Economic Forum selected her as a member of the Forum of Young Global Leaders. She also serves as a member of the Whitehead Board of Associates. She holds an MD from Harvard Medical School, and received a BSc in Biological Sciences and a BA in Art History from Stanford University.

Lawrence Keeley
President
Doblin Inc.

 

 

Larry Keeley, a strategist who develops innovation methods, is co-founder of Doblin Inc., a firm known for pioneering systems for improving innovation success rates, and now a member of Monitor Group, Cambridge MA, where Keeley is a Partner. He has worked with global companies on innovation effectiveness, including Apple, Baxter, Citigroup, Coca-Cola, GE, Monsanto, Motorola, Novartis, Pfizer, Texas Instruments and Whirlpool. He lectures and publishes regularly and he has written The Taming of the New. BusinessWeek recently named him one of seven leading Innovation Gurus. He teaches graduate innovation strategy at the Institute of Design in Chicago and lectures at the University of Chicago. Formerly a Senior Fellow of the Center for Business Innovation, he is also a board member for WBEZ-FM, Chicago’s public radio station.

Wolfgang Klietmann, MD, OPM 12
President and Medical Director, Mediconsulting, Inc.
Vice President, HBS Health
Co-Chair, HBS Health 8th Annual Health Industry Conference

Wolfgang Klietmann heads an international healthcare consulting company and is an appointed Lecturer in Pathology at Harvard Medical School. Previously on staff of the Department of Pathology at Massachusetts General Hospital, he also performed research as an Associate Scientist at the Wistar Institute of the University of Pennsylvania, headed a research group at the Max-Planck-Institute for Virus Research, and served on the medical faculty of the University of Tuebingen. He was Founder and Physician-in-Chief of a leading Institute of Laboratory Medicine in Germany. He received his medical education at the University of Freiburg (Germany), and at the Sorbonne and the University of Paris Medical School (France). He is a Fellow of the College of American Pathologists. He was recently elected Co-Chair of the Community Relations Committee and ex officio member of the Executive Committee for the 2007 BIO International Convention.

William H. (Hank) Kucheman
Senior Vice President and Group President, Interventional Cardiology
Boston Scientific Corporation

 

Prior to his current position, William Kucheman had served as Senior Vice President of Marketing; Vice President, Corporate Marketing; and Vice President, Strategic Marketing for Boston Scientific. Before joining the company, he held a variety of management positions in sales and marketing for SCIMED, Charter Medical Corporation, and Control Data Corporation. He began his career at the US Air Force Academy Hospital and later was Healthcare Planner, Office of the Surgeon General, for the US Air Force Medical Service. He has also served on several industry boards including the board of directors of the Global Health Exchange and AdvaMed. He earned a BS and a MBA from Virginia Polytechnic Institute.

Laura Mauri, MD, MSc
Chief Scientific Officer
Harvard Clinical Research Institute

 

 

Lauri Mauri has become an internationally recognized leader in interventional cardiology research by virtue of her analytical rigor and creativity to clinical investigation. She is an interventional cardiologist in the Cardiovascular Division of the Brigham and Women’s Hospital and teaches clinical trial methodology at Harvard Medical School. At Harvard Clinical Research Institute, she previously held the positions of Medical Director of Trial Design and Associate Chief Scientific Officer before being promoted to Chief Scientific Officer. She has particular expertise in the use of statistical methods in clinical research, applicable to a broad range of disciplines. She is a graduate of Harvard College, Harvard Medical School, and the Harvard School of Public Health. 

Kirk Ririe
Founder
Idaho Technology

 

 

Since 1991, Kirk Ririe has worked closely with University of Utah researchers to commercialize several generations of bio-threat identification systems. Working with U. Pathologist Carl Wittwer, PhD, MD, he launched the LightCycler Instrument, which was subsequently licensed to Roche Diagnostics GmbH. A ruggedized version of the LightCycler serves as the pathogen identification system for the US Department of Defense (JBAIDS). Most recently, he has managed the development of the FilmArray, a device capable of testing a biological sample for dozens of pathogens using nested-multiplex PCR in a plastic pouch format.

Sean Salmon
General Manager and Vice President
Coronary and Peripheral Business
Medtronic

 

Sean Salmon oversaw the international launch of Endeavor, Medtronic's drug eluting stent, which now has more than 20 percent of the world's market share in countries where it competes. Before joining Medtronic, he held executive positions at Surgi-Vision and Euro RSCG Life. Previously at Johnson & Johnson, he was Senior Product Director of Interventional Systems, and later Group Director of Marketing for its Cordis division. He was National Sales Training Manager and then Product Manager at CR Bard. He has won numerous honors, including six recognitions for various product launches and two Medtronic Star of Excellence awards. He has an MBA from the Kellogg School of Management and a BS in Applied Physiology from Boston University.

Mark Schneider, MBA '93
Chairman of the Managing Board
Fresenius AG

Ulf M. (“Mark”) Schneider, is the President and CEO of Fresenius AG. He joined Fresenius in November 2001 and served as Chief Financial Officer of Fresenius Medical Care before assuming his current position in May 2003. Previously, he was Group Finance Director for Gehe UK plc., a pharmaceutical wholesale and retail distributor in Coventry, England. He holds a Lic. oec. degree in Finance and Accounting, a PhD in Economics from the University of St. Gallen and an MBA from Harvard University. Born and raised in Germany, he became an American citizen in 2003.

Sara Sievers
Senior Program Officer
Global Health Advocacy
Bill and Melinda Gates Foundation

Before taking up her present position, Sara Sievers directed policy, research, and advocacy for the Association Francois-Xavier Bagnoud (FXB), a global voice for children living with HIV/AIDS. Previously, she served as founding Executive Director of both the Center for Globalization and Sustainable Development at Columbia University and the Center for International Development at Harvard University. She is a former US Foreign Service Officer. She received her BA from Harvard University in Comparative Government, and an MBA from MIT.

Duncan J. Stewart, MD
CEO and Scientific Director
Ottawa Health Research Institute

 

 

Duncan Stewart received an MD from McGill University, where he also performed residency training in Internal Medicine and Cardiology.  Ater a research fellowship in Germany, he became Assistant Professor of Medicine and staff cardiologist at the Royal Victoria Hospital. Following that, he became Head of Cardiology at St. Michael’s Hospital. In 1997, he became the Director of Cardiology of the University of Toronto and was awarded the Dexter Man Chair of Cardiology.  He was promoted in 1999 to Full Professor of Medicine there, and in 2003 he became the Associate Director of Research at St. Michael’s Hospital.  In 2003 he was appointed leader of the Regenerative Medicine Program of the McLaughlin Centre for Molecular Medicine, and in 2005 he became Director. He now also serves as VP of Research for The Ottawa Hospital.

Steven Wardell, MBA '00
Executive Vice President, Finance
and Corporate Development Officer
Informed Clinical Sciences Corp.
Roundtable Chair, HBS Health 8th Annual Industry Conference

Steven Wardell is a health-industry corporate finance professional with
transactional and company-building experience in health services,
pharmaceuticals, biotechnology, and medical devices. Before joining IC
Sciences, he served as Vice President of Finance and Senior Director of
Business Development for Artisan Pharma, Inc., a Phase III, Boston-based
biotech start-up. Prior to Artisan Pharma, Inc., he was a Principal at
Apeiron Partners, a Boston-based health-industry investment bank and
venture capital fund. Mr. Wardell also has worked on Wall Street, where
he participated in over $20 billion worth of M&A and financing
transactions at Citigroup (Salomon Smith Barney) in the healthcare,
technology, and industrial sectors. He holds an MBA from Harvard
Business School, an MPhil in Economics from Cambridge University, and a
BA from Harvard College.

Thomas Zeltner
Director General
Swiss Federal Office of Public Health

 

Thomas Zeltner has held his post since 1991. His national responsibilities range from food, drug and chemical safety to infectious disease control; health promotion and disease prevention programs, regulation of medical training and research to Social Health Insurance. As Secretary of State for Health he was a key member of the WHO executive board (2000-2002) and chaired Committee B of the last World Health Assembly (2007). He has an MD and a law degree from the University of Berne, where he was medical director of its university hospital (1989 -1990). He was a Research Associate at the Harvard School of Public Health (1986 -1988).

 

©2007 Harvard Business School Health Industry Alumni Association.